JNJ

188.52

-0.24%↓

ABT

122.83

-0.61%↓

TMO

558.09

-1.75%↓

ISRG

532.82

-0.29%↓

DHR

213.5

-0.98%↓

JNJ

188.52

-0.24%↓

ABT

122.83

-0.61%↓

TMO

558.09

-1.75%↓

ISRG

532.82

-0.29%↓

DHR

213.5

-0.98%↓

JNJ

188.52

-0.24%↓

ABT

122.83

-0.61%↓

TMO

558.09

-1.75%↓

ISRG

532.82

-0.29%↓

DHR

213.5

-0.98%↓

JNJ

188.52

-0.24%↓

ABT

122.83

-0.61%↓

TMO

558.09

-1.75%↓

ISRG

532.82

-0.29%↓

DHR

213.5

-0.98%↓

JNJ

188.52

-0.24%↓

ABT

122.83

-0.61%↓

TMO

558.09

-1.75%↓

ISRG

532.82

-0.29%↓

DHR

213.5

-0.98%↓

Search

Quidel Corp

Fechado

26.68 -0.82

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.73

Máximo

27.15

Indicadores-chave

By Trading Economics

Funcionários

6,600

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+46.35% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

300M

1.7B

Abertura anterior

27.5

Fecho anterior

26.68

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de nov. de 2025, 22:13 UTC

Ganhos

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 de nov. de 2025, 21:23 UTC

Ganhos

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 de nov. de 2025, 23:43 UTC

Conversa de Mercado

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 de nov. de 2025, 23:34 UTC

Conversa de Mercado

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 de nov. de 2025, 21:00 UTC

Ganhos

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 de nov. de 2025, 21:00 UTC

Ganhos

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 de nov. de 2025, 21:00 UTC

Ganhos

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 de nov. de 2025, 20:55 UTC

Ganhos

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 de nov. de 2025, 20:55 UTC

Ganhos

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 de nov. de 2025, 20:55 UTC

Ganhos

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 de nov. de 2025, 20:46 UTC

Ganhos

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 de nov. de 2025, 20:46 UTC

Ganhos

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 de nov. de 2025, 20:45 UTC

Ganhos

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 de nov. de 2025, 20:44 UTC

Ganhos

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 de nov. de 2025, 20:43 UTC

Ganhos

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 de nov. de 2025, 20:42 UTC

Ganhos

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 de nov. de 2025, 20:41 UTC

Ganhos

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 de nov. de 2025, 20:40 UTC

Ganhos

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 de nov. de 2025, 20:39 UTC

Ganhos

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 de nov. de 2025, 20:37 UTC

Ganhos

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 de nov. de 2025, 20:37 UTC

Ganhos

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 de nov. de 2025, 20:37 UTC

Ganhos

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 de nov. de 2025, 20:36 UTC

Ganhos

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 de nov. de 2025, 20:35 UTC

Ganhos

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 de nov. de 2025, 20:35 UTC

Ganhos

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 de nov. de 2025, 20:35 UTC

Ganhos

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 de nov. de 2025, 20:34 UTC

Ganhos

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 de nov. de 2025, 20:33 UTC

Ganhos

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 de nov. de 2025, 14:27 UTC

Ganhos

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 de nov. de 2025, 14:25 UTC

Ganhos

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

46.35% parte superior

Previsão para 12 meses

Média 39.5 USD  46.35%

Máximo 62 USD

Mínimo 26 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

4

Comprar

3

Manter

1

Vender

Informação Financeira

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat